Compounded GLP-1 Recall: How to Check Your Vial

Seeing "GLP-1 recall" in your feed while there's a vial in your fridge is not a fun combo. Here's the short version, then the details.

The short version

One compounding outsourcing facility, Apothecary Pharma in Cary, North Carolina, is recalling specific lots of compounded tirzepatide, plus one lot of NAD+. If your vial label doesn't say Apothecary Pharma, this recall isn't about your vial. If it does, don't use it and call your prescriber.

What was recalled

According to the FDA Enforcement Report (event 99952):

  • Product: Tirzepatide Injection, 18 mg/mL, 4 mL sterile multi-dose vial, labeled Apothecary Pharma, LLC, Cary, NC. NDC 85091-001-18.
  • Lots: AP-202622, AP-202623, AP-202624 and AP-202625, plus AP-202627 through AP-202644. Lot AP-202626 is not on the list. Beyond-use dates run from Oct 7, 2026 through Nov 26, 2026.
  • Also recalled: Apothecary NAD+ Injection, 200 mg/mL, 6 mL vial, NDC 85091-011-06, lot AP-202647.
  • Reason: "Lack of Assurance of Sterility." That means the facility can't guarantee the product is sterile. It does not mean contamination was found.
  • Scope: Distributed nationwide. A voluntary recall started by the company on Sept 24, 2026, classified by the FDA as Class II in October 2026. Customers were notified by letter.
  • Status: Ongoing as of our last check on Oct 21, 2026.

Apothecary Pharma is registered with the FDA as a 503B outsourcing facility, a type of compounder that can make larger batches and ship them to clinics and providers.

What "Class II" means

The FDA sorts recalls into three classes. Class II is the middle one: using the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote. Class I is the most serious; Class III is the least.

Translation: take it seriously, don't panic.

How to check your vial in 60 seconds

Grab the vial or the box and look for three things:

  1. Pharmacy name. Compounded medications are labeled with the pharmacy or facility that made them. This recall is Apothecary Pharma, LLC only.
  2. Lot number. Usually printed near the beyond-use date. Recalled tirzepatide lots start with "AP-2026": AP-202622 to AP-202625 and AP-202627 to AP-202644. The recalled NAD+ lot is AP-202647.
  3. Beyond-use date (BUD). Compounded medications carry a beyond-use date instead of a standard expiration date. Recalled tirzepatide lots have BUDs between Oct 7 and Nov 26, 2026.

If the pharmacy name doesn't match, you're done. If it does and the lot matches, keep reading.

If your vial matches

  • Don't use it. Set it aside. Don't toss it until your prescriber or the pharmacy tells you how to return or dispose of it.
  • Call your prescriber. They'll tell you what to do with the vial and how to keep your treatment on track.
  • Watch for anything off. Redness, swelling, warmth, or pain at an injection site that gets worse, or a fever, deserves a call to a clinician. Severe symptoms mean urgent care.
  • Report it. You or your clinician can report a problem with a medication to the FDA through MedWatch.

Five questions to ask any compounded GLP-1 provider

A recall is a good moment to know who's behind your medication. Fair questions for any telehealth company, including us:

  1. Which pharmacy compounds my medication, and is it state-licensed?
  2. Is it a 503A pharmacy or a 503B outsourcing facility?
  3. Does my label show the pharmacy name, lot number, and beyond-use date?
  4. How will you contact me if a lot I received is recalled?
  5. Who do I call if something seems wrong with a vial?

If a provider can't answer those quickly, that's information too.

Where Fitish fits

Every Fitish compounded medication is prepared by a state-licensed compounding pharmacy and prescribed only after a licensed provider reviews your intake. If you have a question about your own vial, message your care team in the patient portal and we'll check the label details with you.

Curious about compounded GLP-1s in general? Our Patient's Guide to Compounded GLP-1s covers how they're made and what to look for. Comparing options? Start with Semaglutide vs Tirzepatide. Your provider walks you through each route and you choose the one that fits.

Explore Fitish RX

Common questions

Is all compounded tirzepatide being recalled?
No. The FDA Enforcement Report covers specific lots of tirzepatide injection from one facility, Apothecary Pharma, LLC in Cary, NC. Check your vial's pharmacy name and lot number.

Which lot numbers are part of the compounded tirzepatide recall?
Tirzepatide Injection 18 mg/mL, 4 mL vials, lots AP-202622 through AP-202625 and AP-202627 through AP-202644, with beyond-use dates from Oct 7 to Nov 26, 2026. Lot AP-202626 is not included. One NAD+ lot, AP-202647, is also recalled.

Why was it recalled?
The reason listed is "Lack of Assurance of Sterility," meaning sterility could not be guaranteed. The FDA classified it as a Class II recall.

What should I do if my vial is on the list?
Don't use it. Contact your prescriber for instructions on returning or disposing of it and on continuing treatment. Report any problems to the FDA through MedWatch.

Is semaglutide part of this recall?
The FDA Enforcement Report for this event lists tirzepatide and one NAD+ product. No semaglutide is listed.

Last updated Oct 29, 2026. This page is for general education and is not medical advice. Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality. Recall details can change; check the FDA Enforcement Report for the latest. Talk to your prescriber about your treatment.